Put companies on watchlist
PolyPeptide Group
ISIN: CH1110760852
WKN: A3CNHV
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PolyPeptide Group · ISIN: CH1110760852 · EQS - Company News (42 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 2101938
18 March 2025 07:00AM

PolyPeptide publishes invitation to the annual General Meeting 2025


PolyPeptide Group / Key word(s): AGMEGM
PolyPeptide publishes invitation to the annual General Meeting 2025

18.03.2025 / 07:00 CET/CEST


Media release

PolyPeptide publishes invitation to the annual General Meeting 2025

Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug.

At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug (the “AGM 2025”), five current members of the Board of Directors will stand for re-election. Beat In-Albon has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Mr. In-Albon for his dedicated service and valuable contributions. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee. As announced on 11 March 2025, the Board of Directors further proposes Jo LeCouilliard for election as new independent member of the Board of Directors, and upon election it is expected that Ms. LeCouilliard will join the Audit and Risk Committee.

The Board of Directors further proposes to the AGM 2025 the introduction of a capital band in a new art. 3a of the Company's Articles of Association and the introduction of a conditional share capital for financing purposes and finance instruments in a new art. 3c of the Company's Articles of Association. The capital band shall provide the Board of Directors with the flexibility to increase the Company’s share capital within a predefined range, thereby enhancing the Company's financial and strategic agility. The conditional share capital shall increase the Company's financing and refinancing flexibility.

Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2024 as well as the Remuneration Report 2024 in separate consultative vote.

The invitation to the AGM 2025 with the detailed proposals and explanations can be found on the Company’s website.

Contact

PolyPeptide Group AG

Michael Stäheli

Head of Investor Relations & Corporate Communications

michael.staeheli@polypeptide.com

T: +41 43 502 0580

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide.com.  

@PolyPeptide – follow us on LinkedIn

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.



End of Media Release


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2101938

 
End of News EQS News Service

2101938  18.03.2025 CET/CEST

Visual performance / price development - PolyPeptide Group
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.